Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy

Table 5 Treatment delivery and grade ≥ 3 adverse events

	All, n = 148	High GNRI, n = 110	Low GNRI, n = 38	p-value
Cycles of platinum-based therapy	4 (1–8)	4 (1–8)	2.5 (1–6)	< 0.001
Completion of platinum-based chemotherapy	98 (66.2)	83 (75.5)	15 (39.5)	< 0.001
Reasons for discontinuation				0.423
Progressive disease	31 (62.0)	19 (70.4)	12 (52.2)
Adverse events	5 (14.0)	5 (18.5)	7 (30.4)
Others	12 (24.0)	3 (11.1)	4 (17.4)
Treatment delay	21 (14.2)	16 (14.6)	5 (13.2)	1.000
Dose reduction	39 (26.4)	24 (21.8)	15 (39.5)	0.053
Grade ≥ 3 adverse events	63 (42.6)	42 (38.2)	21 (55.3)	0.087

Data are expressed as the median (range) or number (%). The p values indicate comparisons between high and low GNRI group
GNRI geriatric nutritional risk index

ISSN: 1471-2466